Welcome to our dedicated page for Prelude Therapeutics news (Ticker: PRLD), a resource for investors and traders seeking the latest updates and insights on Prelude Therapeutics stock.
Prelude Therapeutics Incorporated reports news around its precision oncology pipeline, including clinical and preclinical programs aimed at genetically and epigenetically defined cancer targets. Recurring updates cover PRT12396, a mutant-selective JAK2V617F inhibitor being developed for certain myeloproliferative neoplasms, and PRT13722, an orally bioavailable selective KAT6A degrader being developed in breast cancer.
Company announcements also address FDA and IND-related developments, preclinical data presentations at oncology and hematology meetings, financial results, investor presentations, executive appointments, and capital-structure activity tied to its Nasdaq-listed common stock.
Prelude Therapeutics (Nasdaq: PRLD) announced its Q1 2021 financial results and provided updates on clinical trials. Key developments include enrollment in multiple expansion cohorts for PRT543, a PRMT5 inhibitor, and ongoing dose escalation in PRT1419, an MCL1 inhibitor. Initial clinical data for PRT543 and PRT811 is expected in 2H21. As of March 31, 2021, the company reported $363 million in cash, with a net loss of $21.3 million or $0.47 per share. R&D expenses rose to $16.5 million. The company anticipates sufficient funds to support operations into 2023.
Prelude Therapeutics, a clinical-stage precision oncology company (Nasdaq: PRLD), has announced that CEO Kris Vaddi, PhD, will present at the BofA Securities 2021 Virtual Health Care Conference on May 12, 2021, at 5:00 p.m. ET. The presentation will be available via live webcast on the Company’s investor website, with a replay accessible later.
Prelude is developing innovative oral drug candidates for critical cancer pathways, including PRT543 and PRT811, both in Phase 1 trials targeting advanced tumors and glioblastoma. Their pipeline also includes PRT1419, a promising MCL1 inhibitor.
Prelude Therapeutics (Nasdaq: PRLD) reported its financial results for Q4 and full year 2020, highlighting a net loss of $19.3 million for Q4 and $56.9 million for the year. The company completed the dose escalation of its lead product PRT543 and plans to start expansion cohorts in Q2 2021. Prelude also announced ongoing trials for PRT1419 and PRT811, with anticipated data readouts in 2H21. The successful public offering raised $172.5 million, and cash reserves of $218.3 million are expected to support operations into 2023.
Prelude Therapeutics (Nasdaq: PRLD) announced management participation in three virtual investor conferences. Key details include:
- Barclays Global Healthcare Conference: March 10, 2021, at 8:35 a.m. ET.
- Morgan Stanley Virtual Healthcare Corporate Access Day: One-on-one meetings on March 16, 2021.
- Oppenheimer 31st Annual Healthcare Conference: March 17, 2021, at 3:50 p.m. ET.
Webcasts available on the company's website, where replays will also be accessible.
Prelude Therapeutics announced the completion of an upsized public offering, selling 2,583,334 shares of voting common stock and 291,666 shares of non-voting common stock at $60.00 per share, raising approximately $172.5 million in gross proceeds. This offering included the underwriters' full option for an additional 375,000 shares. The offering was managed by Morgan Stanley, Goldman Sachs, BofA Securities, and Barclays. Prelude develops precision oncology therapies, with candidates targeting PRMT5 and MCL1 pathways, currently in various phases of clinical trials.
Prelude Therapeutics has announced a public offering of 2,208,334 shares of voting common stock and 291,666 shares of non-voting common stock at $60.00 per share, aiming to raise approximately $150 million. The offering closes on January 11, 2021, with underwriters Morgan Stanley, Goldman Sachs, BofA Securities, and Barclays involved. A 30-day option for underwriters to purchase an additional 375,000 shares has been granted. This funding will support Prelude's clinical-stage oncology developments, including advanced candidates targeting critical cancer pathways.
Prelude Therapeutics (Nasdaq: PRLD) has initiated a public offering of 1,750,000 shares of common stock under a filed registration statement. The company will sell all shares, with a potential 30-day option for underwriters to purchase up to an additional 262,500 shares. The offering is led by Morgan Stanley, Goldman Sachs, BofA Securities, and Barclays. Completion of the offering is not guaranteed, as the registration statement with the SEC has yet to become effective, and no sales can occur until it does.
Prelude Therapeutics completed its IPO, raising approximately $181.9 million. The company reported a net loss of $16.8 million for Q3 2020, an increase from $6.7 million in Q3 2019. Clinical updates include a partial response in a glioblastoma multiforme patient during the PRT811 trial and a durable complete response in an ovarian cancer patient in the PRT543 trial. Prelude's cash and equivalents stood at $234.8 million as of September 30, 2020, indicating robust financial positioning for upcoming clinical trials.
Prelude Therapeutics has priced its initial public offering of 8,325,000 shares at $19.00 per share, aiming for gross proceeds of approximately $158.2 million. The offering will close on September 29, 2020, and shares are set to trade on the Nasdaq under the ticker PRLD starting September 25, 2020. An additional 1,248,750 shares may also be purchased by underwriters within 30 days. Morgan Stanley, Goldman Sachs & Co. LLC, and BofA Securities are managing the offering.